CCL17 and esophageal squamous cell carcinoma: Furthermore, Eca109 cells were treated with exogenous CCL17 or co-treated with exogenous CCL17 and CCR4 antagonist AZD2098 in order to further expound the oncogenic role of CCL17 in ESCC and to thoroughly elucidate the underlying mechanisms.